Table 2.
Univariate analysis comparing patients with esophageal cancer with and without EUS evaluation
| Variable | No EUS or CT-PET n=4,723 |
EUS n=524 |
p value |
|---|---|---|---|
| Age (mean, SD) | 76.3 (6.7) | 74.5 (5.9) | <0.0001 |
| Males (n, %) | 3,296 (69.8) | 384 (73.3) | 0.09 |
| Race | |||
| White (n, %) | 4,038 (85.5) | 480 (91.6) | 0.0002 |
| Black (n, %) | 420 (8.89) | 20 (3.8) | |
| Other (n, %) | 265 (5.61) | 24 (4.6) | |
| Registry Site | <0.0001 | ||
| Medicaid enrollment: No (n, %) | 4,503 (95.3) | 496 (94.7) | 0.48 |
| Histology | |||
| EAC | 2,488 (52.7) | 348 (66.4) | <0.0001 |
| ESCC | 1,835 (38.85) | 145 (27.7) | |
| Other | 400 (8.47) | 31 (5.9) | |
| Charlson Co-morbidity Index (n, %) | |||
| 0 | 2,883 (61.04) | 334 (63.7) | 0.61 |
| 1 | 1058 (22.4) | 113 (21.6) | |
| 2 | 452 (9.57) | 46 (8.8) | |
| ≥ 3 | 330 (6.99) | 31 (5.9) | |
| Stage (n, %) | |||
| 0 (in situ) | 133 (2.8) | 20 (3.8) | <0.0001 |
| 1(localized) | 1,568 (33.2) | 183 (34.9) | |
| 2 (regional) | 1,466 (31.04) | 264 (50.4) | |
| 4 (distant) | 1,556 (33) | 57 (10.9) | |
| Mean survival in days (n, SD) | |||
| 0 (in situ) | 1,303 (1178.7) | 1,566.2 (901.5) | 0.34 |
| 1(localized) | 741.5 (900.6) | 1,330.7 (1071.1) | <0.0001 |
| 2 (regional) | 508.5 (690.2) | 710.2 (774.4) | <0.0001 |
| 4 (distant) | 230.4 (372.3) | 431.3 (534.1) | <0.0001 |
| Therapy (n, %) | |||
| EMR/Ablation | 79 (1.67) | 39 (7.4) | <0.0001 |
| Chemotherapy | 1,500 (31.8) | 197 (37.6) | 0.007 |
| Radiotherapy | 1,962 (41.5) | 237 (45.2) | 0.10 |
| Esophageal Resection | 163 (3.4) | 32 (6.1) | 0.002 |
| Chemotherapy and radiation | 1,072 (22.7) | 145 (27.7) | 0.01 |
| Chemotherapy, radiation and surgery | 10 (0.21) | 1 (0.2) | 0.92 |
Abbreviations: EAC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; SD, standard deviation.